NIH Scientists Engineer DFNZ: A Nitazene-Derived Opioid That Delivers Pain Relief Without Respiratory Depression or Addiction

The discovery challenges a decades-old assumption: that mu-opioid receptor agonism, the mechanism underlying all clinically used opioids, is inextricably linked to lethal side effects. DFNZ suggests that with precise molecular engineering, it may be possible to decouple analgesia from the physiological cascades that cause addiction and death.

Nitazenes: From Abandoned Research to Street Crisis

Nitazenes were first synthesized in the mid-20th century as part of pharmaceutical research into new pain medications. Early testing revealed they were extraordinarily potent—far stronger than morphine—but their development was discontinued because they were deemed too dangerous for medical use. The compounds faded into obscurity, relegated to academic literature and forensic databases.

In recent years, however, nitazenes have re-emerged as a public health threat. Illicitly manufactured versions have been detected in the drug supply across North America and Europe, contributing to overdose outbreaks and complicating harm reduction efforts. Their potency rivals or exceeds that of fentanyl, and standard naloxone dosing may not fully reverse their effects.

Rather than treat nitazenes solely as a toxicological problem, the NIH team saw an opportunity. If the class could be re-engineered—if its selectivity for the mu-opioid receptor could be harnessed while its lethality was eliminated—it might yield a safer therapeutic.

"Our goal was to study the profile, or pharmacology, of these drugs," said Dr. Michael Michaelides, senior author of the Nature study and investigator at the National Institute on Drug Abuse. "We wanted to decrease the potency and create a potential therapeutic. What we discovered exceeded our expectations."

From FNZ to DFNZ: Tracking a Metabolite

The research team began by studying FNZ, one member of the nitazene family, using advanced imaging techniques to track its movement through the brain. They observed something unexpected: FNZ entered and exited the brain rapidly, spending only minutes in neural tissue. Yet its analgesic effects persisted for hours.

This discrepancy suggested that FNZ itself was not responsible for the prolonged pain relief. Instead, the researchers hypothesized that the body was converting FNZ into a metabolite—a breakdown product—that had its own pharmacological activity. Further investigation confirmed the presence of DFNZ, a derivative produced through metabolic processing.

When the team isolated and tested DFNZ, they found it to be a "superagonist" at the mu-opioid receptor, meaning it activated the receptor with very high efficacy. But unlike traditional opioids, which produce rapid dopamine surges and profound respiratory suppression, DFNZ behaved differently. It induced a slower, more controlled release of dopamine, and at therapeutic doses, it did not depress breathing.

Pain Relief Without Respiratory Depression

Respiratory depression is the leading cause of death in opioid overdoses. When opioids bind to receptors in the brainstem, they slow or stop breathing, leading to hypoxia, organ failure, and death. This side effect is dose-dependent but present to some degree with all clinically used opioids, including morphine, oxycodone, and fentanyl.

In animal models, DFNZ provided potent and sustained pain relief—comparable to or exceeding that of morphine—without causing significant respiratory depression. Mice treated with DFNZ at analgesic doses maintained normal breathing rates, even after repeated administration. This separation of analgesia from respiratory suppression is virtually unprecedented among full mu-opioid receptor agonists.

The mechanism underlying this dissociation is not yet fully understood, but researchers believe it may involve biased agonism or differential signaling pathways downstream of receptor activation. DFNZ appears to engage some therapeutic pathways while avoiding others that lead to harm. If this hypothesis is correct, it could open a new frontier in opioid pharmacology, one where receptor selectivity and signaling bias are leveraged to design drugs that maximize benefit and minimize risk.

No Tolerance, No Dependence, No Withdrawal

Tolerance—the need for escalating doses to achieve the same effect—is a hallmark of chronic opioid use. Over time, patients taking opioids for pain often require higher and higher doses, increasing their risk of overdose and dependence. DFNZ did not produce tolerance in animal studies. Repeated dosing over multiple days maintained consistent analgesic efficacy without dose escalation.

Even more striking, DFNZ did not produce significant physical dependence. When administration was stopped abruptly, animals did not exhibit the severe withdrawal symptoms typical of opioid cessation: agitation, tremor, diarrhea, hypersensitivity to pain. Aside from occasional mild irritation, withdrawal was negligible.

This finding has profound implications. Physical dependence is a major barrier to discontinuing opioid therapy, even when it is no longer medically necessary. Patients fear withdrawal, and clinicians struggle to taper doses without causing distress. A medication that provides effective pain relief without inducing dependence could transform the management of acute and chronic pain.

A Different Kind of Reward Signal

Addiction is driven by the brain's reward system. Opioids cause a surge of dopamine in the nucleus accumbens, a brain region central to motivation and reinforcement. This flood of dopamine produces euphoria and reinforces drug-taking behavior, creating a powerful incentive to seek and use the drug again.

DFNZ did cause animals to self-administer the drug in experimental settings, indicating some rewarding effect. But the pattern of use was markedly different from that seen with morphine, heroin, or fentanyl. When DFNZ was removed, animals quickly stopped seeking it. There was no persistent drug-seeking behavior, no compulsive lever-pressing, no desperation for more.

This suggests that DFNZ's interaction with the reward system is fundamentally different. The slower, more regulated dopamine release may produce a milder reinforcement signal—enough to make the drug preferable to placebo, but not enough to drive compulsive use. In practical terms, this could mean a medication that patients find helpful and tolerable, but not one that hijacks motivation and decision-making in the way that addictive opioids do.

"DFNZ has an unprecedented pharmacology for an opioid," Michaelides said. "It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety. Its capacity to be administered at therapeutic doses without producing respiratory depression is very important."

Dual Promise: Pain Management and Addiction Treatment

If DFNZ proves effective and safe in human trials, its applications could extend beyond pain management. Medication-assisted treatment for opioid use disorder—methadone, buprenorphine—work by occupying mu-opioid receptors without producing the intense euphoria or respiratory depression of illicit opioids. They stabilize brain chemistry, reduce cravings, and allow patients to engage in recovery.

DFNZ's unique profile suggests it could serve a similar role. Its ability to activate opioid receptors without inducing strong reinforcement or physical dependence might make it useful for managing withdrawal, supporting long-term recovery, or transitioning patients off more dangerous opioids. It could also be explored as a bridge therapy in settings where buprenorphine is unavailable or poorly tolerated.

The NIH team is cautious about overstating the implications. The compound has only been tested in animals, and the history of drug development is littered with preclinical successes that failed in human trials. But the data are compelling enough to warrant further investigation.

The Road to Human Trials

Before DFNZ can be tested in humans, additional animal studies are needed to establish dosing ranges, long-term safety, and potential interactions with other medications. The NIH team is conducting these studies now, with the goal of applying for Investigational New Drug status from the Food and Drug Administration.

If approved, Phase I trials would begin with small cohorts of healthy volunteers to assess safety and pharmacokinetics. Phase II trials would test efficacy in patients experiencing pain, and Phase III trials would compare DFNZ to standard treatments in larger populations. This process typically takes years, and success is far from guaranteed.

Even if DFNZ advances through clinical development, questions remain. Will the compound behave the same way in humans as it does in mice? Will individual genetic variation affect its metabolism or efficacy? Could long-term use reveal risks not apparent in short-term animal studies? These are empirical questions that can only be answered through rigorous testing.

A Glimpse of What's Possible

For decades, the medical community has operated under the assumption that opioid analgesia comes with unavoidable trade-offs. Pain relief, tolerance, dependence, overdose risk—these were treated as a package deal, inherent to the pharmacology of the mu-opioid receptor.

DFNZ challenges that assumption. It demonstrates that with precise molecular design, it may be possible to retain the therapeutic benefits of opioids while shedding the harms. Whether DFNZ itself becomes a medicine or serves as a proof of concept for a new generation of analgesics, its discovery is significant.

The opioid crisis has claimed hundreds of thousands of lives in the United States alone. It has devastated families, strained health systems, and exposed deep failures in how we prescribe, regulate, and think about pain. A safer opioid won't solve the crisis on its own—structural issues around access to care, economic inequality, and drug policy remain—but it could offer a tool that clinicians have desperately needed.

Chronic pain affects an estimated 50 million Americans. Many live with inadequate relief because the risks of opioid therapy outweigh the benefits. Others become dependent on medications they no longer need but cannot safely stop. Post-surgical patients, cancer patients, and trauma victims all face the same calculus: how much pain is tolerable, and how much risk is acceptable?

DFNZ suggests a future where that calculus changes. Where pain can be treated aggressively without fear of respiratory arrest. Where patients can use opioids for weeks or months without developing tolerance or dependence. Where addiction treatment has another option, one that doesn't require lifelong maintenance or carry its own overdose risk.

That future is not here yet. It may never arrive. But for the first time in a long time, it feels possible.